MTVA

MetaVia Inc. (MTVA) | Rumor.io

MetaVia

MTVA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,406

Bullish sentiment (50-day avg)67%

Price to earnings ratio-0.23

Market capitalization11M

Earnings per share-2.45

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-13M

Social

What share of all stock conversation is about MTVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 9

MetaVia Inc. ($MTVA) is experiencing a downward trend with a potential target of $1.20.
The stock is expected to face resistance at $1.90 if it reverses.
MetaVia presented positive results for its Phase 0 Non-alcoholic Steatohepatitis and Type 2 Diabetes trial for Vanoglipel.

Generated by AI

Sentiment

Of the messages about MTVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	62.94% -5.36
Bearish	—	—	—	37.06% +5.36

Bullish· May 22

$MTVA has the potential to reach $5.50 highs.
The asset's low float and gap shape suggest it may be undervalued, with a catalyst needed to unlock its full potential.
$MTVA has already experienced a significant price increase of +148% in a short period of time, with the possibility of reaching a target of $6.

Bearish· May 22

$MTVA's price action is being compared to a pot leaf, potentially damaging its brand image.
The stock has a high likelihood of retracing to $3.50 due to the 4am kids, who are expected to drive the price down.
$MTVA has already had a significant run and may not have enough volume to sustain further growth.

Generated by AI

Topics

Of the messages about MTVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	34.85%
Analysts	—	—	0%	25.82%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.2%
Macro	—	—	0%	21.94%
Technical Analysis	—	—	0%	17.19%

Announcements· Feb 4

MetaVia Inc. announced positive AI modeling results from its Syntekabio collaboration, validating key disease pathways for its lead asset vanoglipel (DA-1241) and supporting expansion in MASH and potential type 2 diabetes.
The AI analysis confirmed that vanoglipel hits key inflammatory and cardiometabolic targets, reinforcing its potential as a therapeutic option for these diseases.
The collaboration with Syntekabio utilized the DeepMatcher platform to target cardiometabolic and inflammatory diseases, with results confirming strong engagement of vanoglipel with key therapeutic targets.

Technical Analysis· May 22

$MTVA price surged to $5.60, a +148% move from $2.25, with a chart target around $6.
$MTVA is set up for a simple S/D flip setup with a range to $4.5/$5.5+, and a strong break over $3.31 is needed for trend continuation.
$MTVA is showing bullish signals, including a powerful volume surge, a bullish RSI signal, and a bullish flag, with a next key level to test at $4.45 - 4.75.

Generated by AI

Community

Of the messages about MTVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	10.13%
Newcomers	—	—	100%	89.87%

Jun 6

The newcomer is focusing on a potential price increase for MTVA, targeting a goal of $3.
The user believes that MTVA's price will break through the 2.30 level and reach 2.75.
The newcomer predicts a further increase to 3.20, then 3.35, and eventually 3.50, before potentially reaching 3.65 or 3.80.

Generated by AI

News

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Amylyx Pharmaceuticals Inc (AMLX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 MetaVia, Inc. (NASDAQ: MTVA) is currently conducting Part 3 of the Phase 1 study of DA-1726, the company’s oxyntomodulin analog agonist that targets glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), for the treatment of obesity. The

1mo agoYahoo Finance

H.C. Wainwright reiterates MetaVia stock rating on dose milestone

2mo agoInvesting.com

MetaVia completes dose titration in obesity drug trial

2mo agoInvesting.com

MetaVia Announces $4 Million At-The-Market Stock Offering

Detailed price information for Metavia Inc (MTVA-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about MTVA also mention

#	Name	Attention
1	HCW Biologics Inc.HCWB	0%0
2	Snail Inc. Class A Common StockSNAL	0%0
3	SciSparc Ltd.SPRC	0%+0
4	SU Group Holdings LimitedSUGP	0%+0
5	Bluejay Diagnostics Inc.BJDX	0%0
6	GCL Global Holdings LtdGCL	0%0
7	Reliance Global Group Inc.RELI	0%new
8	Abits Group IncABTS	0%new
9	Royalty Management Holding Corp. Common StockRMCO	0%new
10	Agape Atp CorpATPC	0%0

MetaVia Inc.

Healthcare
Biotechnology

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic diseases. The company’s current programs center on obesity and metabolic dysfunction-associated steatohepatitis (MASH), with an emphasis on drug candidates designed to address metabolic regulation, appetite control, and related disease pathways. MetaVia’s pipeline also includes research in type 2 diabetes and other cardiometabolic conditions, reflecting its broader focus on diseases linked to metabolic dysfunction. Based in Cambridge, Massachusetts, MetaVia operates in the biopharmaceutical sector, where its role is to advance early- and mid-stage drug development through clinical testing and therapeutic innovation.

Website

Location

545 Concord Avenue

Cambridge, MA, 02138

United States

Social

What share of all stock conversation is about MTVA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jun 9

MetaVia Inc. ($MTVA) is experiencing a downward trend with a potential target of $1.20.
The stock is expected to face resistance at $1.90 if it reverses.
MetaVia presented positive results for its Phase 0 Non-alcoholic Steatohepatitis and Type 2 Diabetes trial for Vanoglipel.

Generated by AI

Sentiment

Of the messages about MTVA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	62.94% -5.36
Bearish	—	—	—	37.06% +5.36

Bullish· May 22

$MTVA has the potential to reach $5.50 highs.
The asset's low float and gap shape suggest it may be undervalued, with a catalyst needed to unlock its full potential.
$MTVA has already experienced a significant price increase of +148% in a short period of time, with the possibility of reaching a target of $6.

Bearish· May 22

$MTVA's price action is being compared to a pot leaf, potentially damaging its brand image.
The stock has a high likelihood of retracing to $3.50 due to the 4am kids, who are expected to drive the price down.
$MTVA has already had a significant run and may not have enough volume to sustain further growth.

Generated by AI

Topics

Of the messages about MTVA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	34.85%
Analysts	—	—	0%	25.82%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.2%
Macro	—	—	0%	21.94%
Technical Analysis	—	—	0%	17.19%

Announcements· Feb 4

MetaVia Inc. announced positive AI modeling results from its Syntekabio collaboration, validating key disease pathways for its lead asset vanoglipel (DA-1241) and supporting expansion in MASH and potential type 2 diabetes.
The AI analysis confirmed that vanoglipel hits key inflammatory and cardiometabolic targets, reinforcing its potential as a therapeutic option for these diseases.
The collaboration with Syntekabio utilized the DeepMatcher platform to target cardiometabolic and inflammatory diseases, with results confirming strong engagement of vanoglipel with key therapeutic targets.

Technical Analysis· May 22

$MTVA price surged to $5.60, a +148% move from $2.25, with a chart target around $6.
$MTVA is set up for a simple S/D flip setup with a range to $4.5/$5.5+, and a strong break over $3.31 is needed for trend continuation.
$MTVA is showing bullish signals, including a powerful volume surge, a bullish RSI signal, and a bullish flag, with a next key level to test at $4.45 - 4.75.

Generated by AI

Community

Of the messages about MTVA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	10.13%
Newcomers	—	—	100%	89.87%

Jun 6

The newcomer is focusing on a potential price increase for MTVA, targeting a goal of $3.
The user believes that MTVA's price will break through the 2.30 level and reach 2.75.
The newcomer predicts a further increase to 3.20, then 3.35, and eventually 3.50, before potentially reaching 3.65 or 3.80.

Generated by AI

MetaVia

Social

Jun 9

Bullish· May 22

Bearish· May 22

Announcements· Feb 4

Technical Analysis· May 22

Jun 6

Wall Street Analysts Are Bullish on Top Healthcare Picks

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

H.C. Wainwright reiterates MetaVia stock rating on dose milestone

MetaVia completes dose titration in obesity drug trial

MetaVia Announces $4 Million At-The-Market Stock Offering

Also Discussed

MetaVia Inc.

Company Information

Location

Wall Street Analysts Are Bullish on Top Healthcare Picks

MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726

H.C. Wainwright reiterates MetaVia stock rating on dose milestone

MetaVia completes dose titration in obesity drug trial

MetaVia Announces $4 Million At-The-Market Stock Offering

Also Discussed

Social

Jun 9

Bullish· May 22

Bearish· May 22

Announcements· Feb 4

Technical Analysis· May 22

Jun 6